Interpretation of Evidence-based Guidelines on Role of Emerging and Investigational Therapies for Treatment of Adults with Metastatic Brain Tumors Published by CNS in 2019
-
摘要:
脑转移瘤是成人最常见的颅内肿瘤之一。美国神经外科医师大会（Congress of Neurological Surgeons, CNS）曾于2010年发布《脑转移瘤治疗的循证医学指南》，为脑转移瘤的规范化治疗奠定了基础。基于近年来新型疗法的进展，该学会在原指南基础上，回顾分析最新文献，制定了2019版《成人脑转移瘤治疗中新兴及试验性疗法的系统回顾和循证指南》，对高强度聚焦超声、激光间质热疗、放射增敏、免疫调节、分子靶向药物等新型治疗方法进行了讨论。本文将就新指南作一介绍和解读。
Abstract:Metastatic brain tumors are the most common intracranial tumors among adults. The Congress of Neurological Surgeons(CNS) published Evidence-based Clinical Practice Parameter Guidelines for the Treatment of Patients with Metastatic Brain Tumors in 2010, which set a foundation for standardized treatment of metastatic brain tumors. Based on recent advances in novel and investigational therapies, CNS has established Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapies for the Treatment of Adults with Metastatic Brain Tumors in 2019, focusing on high intensity focused ultrasound, laser interstitial thermal therapy, radiation sensitizers, immune modulators, molecular targeted agents and so on. The guideline is hereby introduced and interpreted.
-
Key words:
- Adult brain metastases /
- Radiosensitizer /
- Local therapy /
- Immunomodulator /
- Molecular targeted drugs
-
作者贡献汤韫钰：文稿设计与撰写范存刚：文稿设计、审阅及指导刘如恩：文稿指导
-
表 1 各疗法的临床试验结果、证据等级及推荐等级
Table 1 Clinical trial results, evidence level and recommendation level for each therapy
下载: 导出CSV
-
[1] Moore AJ, Newell DW. Neurosurgery: Principles and Practice[M].//Amin-Hanjani S, Harsh GR. Tumors: Cerebral Metastases and Lymphoma. London: Springer London, 2005: 281-297.
[2] Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)[J]. Neuro Oncol, 2017, 19(2): 162-174. doi: 10.1093/neuonc/now241
[3] Kalkanis SN, Linskey ME. Evidence-based clinical practice parameter guidelines for the treatment of patients with metastatic brain tumors: introduction[J]. J Neurooncol, 2010, 96(1): 7-10. doi: 10.1007/s11060-009-0065-4
[4] 范存刚, 张庆俊.解读2010年AANS/CNS《脑转移瘤治疗的循证医学指南》[J].中华神经外科杂志, 2010, 26(11): 1047-1049. doi: 10.3760/cma.j.issn.1001-2346.2010.11.031 Fan CG, Zhang QJ. Interpretation of the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2010, 26(11): 1047-1049. doi: 10.3760/cma.j.issn.1001-2346.2010.11.031
[5] Elder JB, Nahed BV, Linskey ME, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors[J]. Neurosurgery, 2019, 84(3): E201-E203. doi: 10.1093/neuros/nyy547
[6] Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline[J]. J Neurooncol, 2010, 96(1): 17-32. doi: 10.1007/s11060-009-0060-9
[7] Ter HaaR G. HIFU Tissue Ablation: Concept and Devices[J]. Adv Exp Med Biol, 2016, 880: 3-20. http://cn.bing.com/academic/profile?id=a30d7c52c30914c34911e407bda92358&encoded=0&v=paper_preview&mkt=zh-cn
[8] Mauri G, Nicosia L, Xu Z, et al. Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer[J]. Br J Radiol, 2018, 91(1083): 20170641. http://cn.bing.com/academic/profile?id=94090b1d70caaf46f09e64bc83d167b4&encoded=0&v=paper_preview&mkt=zh-cn
[9] Hong CS, Deng D, Vera A, et al. Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery[J]. J Neurooncol, 2019, 142(2): 309-317. doi: 10.1007/s11060-019-03097-z
[10] Rao MS, Hargreaves EL, Khan AJ, et al. Magnetic resonance-guided laser ablation improves local control for postradiosurgery recurrence and/or radiation necrosis[J]. Neurosurgery, 2014, 74(6): 658-667; discussion 667. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW2017052520282828
[11] Leuthardt EC, Duan C, Kim MJ, et al. Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier[J]. PLoS One, 2016, 11(2): e0148613. doi: 10.1371/journal.pone.0148613
[12] Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase Ⅲ trial[J]. Int J Radiat Oncol Biol Phys, 2009, 73(4): 1069-1076. doi: 10.1016/j.ijrobp.2008.05.068
[13] Cao KI, Lebas N, Gerber S, et al. Phase Ⅱ randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer[J]. Ann Oncol, 2015, 26(1): 89-94. doi: 10.1093/annonc/mdu488
[14] Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A, et al. Phase Ⅱ randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases[J]. Radiat Oncol, 2013, 8: 209. doi: 10.1186/1748-717X-8-209
[15] Ruge M I, Kickingereder P, Grau S, et al. Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases[J]. J Neurooncol, 2011, 105(1): 109-118. doi: 10.1007/s11060-011-0571-z
[16] Brem S, Meyers CA, Palmer G, et al. Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers[J]. Cancer, 2013, 119(21): 3830-3838. doi: 10.1002/cncr.28307
[17] Ruge MI, Kocher M, Maarouf M, et al. Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases[J]. Strahlenther Onkol, 2011, 187(1): 7-14. doi: 10.1007/s00066-010-2168-4
[18] 郭建贵, 牟永告.胶质瘤的过继细胞免疫治疗[J].中国神经肿瘤杂志, 2013, 11(1): 53-57. http://d.old.wanfangdata.com.cn/Thesis/Y308784 Guo JG, Mu YG. Adoptive Immunotherapy for Glioma[J]. Zhongguo Shen Jing Zhong Liu Za Zhi, 2013, 11(1): 53-57. http://d.old.wanfangdata.com.cn/Thesis/Y308784
[19] Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372(4): 320-330. doi: 10.1056/NEJMoa1412082
[20] Carlino MS, Long GV, Schadendorf D, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial[J]. Eur J Cancer, 2018, 101: 236-243. doi: 10.1016/j.ejca.2018.06.034
[21] Queirolo P, Spagnolo F, Ascierto PA, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases[J]. J Neurooncol, 2014, 118(1): 109-116. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=c9ca69af6d442187e8b3ed08b499af74
[22] Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases[J]. Cancer Immunol Immunother, 2009, 58(8): 1297-1306. doi: 10.1007/s00262-008-0642-y
[23] Cortés J, Dieras V, Ro J, et al. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2015, 16(16): 1700-1710. doi: 10.1016/S1470-2045(15)00373-3
[24] Zhuang H, Yuan Z, Wang J, et al. Phase Ⅱ study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma[J]. Drug Des Devel Ther, 2013, 7: 1179-1186. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_a9238d3b6ece87b63edb1cb2d4aec3c4
[25] Lee SM, Lewanski CR, Counsell N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases[J]. J Natl Cancer Inst, 2014, 106(7). pii: dju151. http://cn.bing.com/academic/profile?id=b0b2a2288d66061845694bdb36bfcfef&encoded=0&v=paper_preview&mkt=zh-cn
[26] Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1312-1318. doi: 10.1016/j.ijrobp.2012.11.042
[27] Azer MW, Menzies AM, Haydu LE, et al. Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib[J]. Cancer, 2014, 120(4): 530-536. doi: 10.1002/cncr.28445
[28] Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study[J]. Eur J Cancer, 2014, 50(3): 611-621. doi: 10.1016/j.ejca.2013.11.002
[29] Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression[J]. J Clin Oncol, 2012, 30(21): 2601-2608. doi: 10.1200/JCO.2011.37.2482
[30] Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, et al. Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review[J]. Cancers (Basel), 2019.11(2). pii: E174. doi: 10.3390/cancers11020174
[31] Rossmeisl JH Jr, Garcia PA, Pancotto TE, et al. Safety and feasibility of the NanoKnife system for irreversible electroporation ablative treatment of canine spontaneous intracranial gliomas[J]. J Neurosurg, 2015, 123(4): 1008-1025. doi: 10.3171/2014.12.JNS141768
